In a previous study, Hsiao et al. demonstrated that EF-24 treatment activates the p38 mitogen-activated protein kinase (MAPK) pathway while attenuating ERK signaling in HL-60 acute myeloid leukemia (AML) cells after 24 hours [5]. The gene discussed is MAPK14; the disease is acute myeloid leukemia.